Recombinant Mycoplasma pneumoniae UPF0134 protein MPN_283 (MPN_283)

What is Recombinant Mycoplasma pneumoniae UPF0134 protein MPN_283?

Recombinant Mycoplasma pneumoniae UPF0134 protein MPN_283 (MPN_283) is a hypothetical protein encoded by the MPN_283 gene (also annotated as MPN283 or A65_orf115) in the Mycoplasma pneumoniae genome. This protein belongs to the UPF0134 family, a group of proteins with conserved sequence motifs whose precise functions remain to be fully characterized. The recombinant form refers to the protein produced in laboratory expression systems (such as E. coli, yeast, baculovirus, or mammalian cells) rather than purified from the native organism, allowing for higher yields and controlled production for research purposes . The protein is typically purified to ≥85% as determined by SDS-PAGE analysis, making it suitable for various biochemical and structural studies .

Why is research on Mycoplasma pneumoniae proteins significant?

Research on Mycoplasma pneumoniae proteins holds substantial significance due to the organism's role as a leading cause of community-acquired pneumonia (CAP) worldwide, particularly among children. M. pneumoniae employs various proteins for host colonization, immune evasion, and pathogenesis. Understanding these proteins provides critical insights into the following aspects:

• Disease Mechanism: M. pneumoniae causes respiratory infections through complex host-pathogen interactions, with certain proteins (like CARDS toxin) serving as key virulence determinants .

• Immune Response: Studies demonstrate that the progression of Mycoplasma pneumoniae pneumonia (MPP) is closely related to host immune responses rather than simply bacterial load . Protein-specific immune reactions may determine disease severity.

• Diagnostic Development: Characterizing unique M. pneumoniae proteins enables the development of more accurate diagnostic assays.

• Therapeutic Targets: Identifying essential proteins provides potential targets for novel antimicrobial strategies, especially important as M. pneumoniae lacks a cell wall and is therefore intrinsically resistant to β-lactam antibiotics.

• Vaccine Development: Protein antigens may serve as candidates for preventive vaccine development.

What expression systems are commonly used to produce recombinant MPN_283?

The production of recombinant MPN_283 can be accomplished using several expression systems, each with distinct advantages depending on research objectives:

The choice of expression system should be guided by the specific research questions being addressed. For basic biochemical characterization, E. coli systems may suffice, while functional studies examining potential host interactions might benefit from eukaryotic expression systems . Each recombinant MPN_283 preparation should be validated for purity (≥85% by SDS-PAGE) and functional activity prior to experimental use.

What purification methods are most effective for isolating recombinant MPN_283?

The purification of recombinant MPN_283 typically follows a multi-step process designed to achieve high purity while maintaining protein functionality:

• Affinity Chromatography: Most recombinant MPN_283 constructs are engineered with affinity tags (His-tag, GST, etc.) allowing for initial capture using immobilized metal affinity chromatography (IMAC) or glutathione affinity columns.

• Ion Exchange Chromatography (IEX): Following affinity purification, IEX can be employed to remove impurities based on charge differences. The theoretical isoelectric point of the protein determines whether cation or anion exchange is more appropriate.

• Size Exclusion Chromatography (SEC): As a polishing step, SEC separates proteins based on molecular size, effectively removing aggregates and degradation products.

• Tag Removal: For functional studies, affinity tags may be removed using specific proteases (TEV, thrombin, etc.), followed by a second affinity step to separate the cleaved protein.

Optimal purification protocols should be validated for each expression system to ensure that the final product meets the required purity standards (≥85% as determined by SDS-PAGE) . Quality control steps should include verification of protein identity by mass spectrometry and assessment of secondary structure by circular dichroism when appropriate.

How might the structure of MPN_283 relate to its potential function in M. pneumoniae pathogenesis?

While specific structural data for MPN_283 is limited, structural analysis approaches can provide valuable insights into its potential functions:

• Homology Modeling: By comparing MPN_283 with structurally characterized proteins from the UPF0134 family, researchers can generate predictive models. These models can reveal conserved structural motifs potentially associated with specific functions.

• Domain Analysis: Computational tools can identify potential functional domains within MPN_283. Many hypothetical proteins contain cryptic domains that suggest roles in protein-protein interactions, nucleic acid binding, or enzymatic activities.

• Structural Motif Recognition: Analysis of MPN_283 sequence may reveal motifs similar to those found in other M. pneumoniae virulence factors, such as the CARDS toxin which possesses both ADP-ribosyltransferase activity and vacuolating capabilities .

Given that M. pneumoniae contains a minimal genome, most proteins serve essential functions. The conservation of MPN_283 in the M. pneumoniae genome suggests functional importance, potentially in cellular processes or host interactions. The structural features might reveal similarities to other proteins involved in pathogenesis, such as those mediating adherence to respiratory epithelium or immune evasion mechanisms.

Emerging evidence on M. pneumoniae pathogenesis suggests that disease progression correlates strongly with host immune responses rather than bacterial load , raising the possibility that proteins like MPN_283 could function as immune modulators that influence disease outcomes through interactions with host defense mechanisms.

What experimental approaches can resolve conflicts between in silico predictions and experimental data for MPN_283?

Resolving discrepancies between computational predictions and experimental findings for MPN_283 requires a systematic multi-method approach:

• Structural Validation:

  • X-ray Crystallography or Cryo-EM: Determine the actual three-dimensional structure of MPN_283 to compare with in silico models

  • NMR Spectroscopy: Valuable for examining protein dynamics and interactions in solution

  • Small-Angle X-ray Scattering (SAXS): Provides lower-resolution structural information in native conditions

• Functional Characterization:

  • Protein Interaction Studies: Yeast two-hybrid, pull-down assays, or crosslinking mass spectrometry to identify interaction partners

  • Enzymatic Assays: Test for predicted enzymatic functions based on structural similarities

  • Mutagenesis: Targeted mutations of predicted functional residues to validate their importance

• Integrative Omics Approaches:

  • Transcriptomics: RNA-seq to determine expression patterns of MPN_283 under different conditions

  • Proteomics: Monitor post-translational modifications or expression changes

  • Metabolomics: Identify metabolic changes associated with MPN_283 expression or deletion

• Computational Refinement:

  • Molecular Dynamics Simulations: Refine structural models based on experimental data

  • Machine Learning Integration: Combine multiple prediction algorithms with experimental data to improve accuracy

• Biological Validation:

  • Gene Knockout/Knockdown: Study the effects of MPN_283 deletion on M. pneumoniae viability and virulence

  • Heterologous Expression: Express MPN_283 in other bacterial species to observe phenotypic effects

When computational predictions and experimental results conflict, researchers should systematically examine assumptions underlying both approaches. For computational predictions, the quality of reference databases, algorithm limitations, and model validation metrics should be assessed. For experimental data, factors such as protein conformation in different experimental contexts, assay sensitivity, and experimental conditions may impact results .

How does MPN_283 expression correlate with virulence in clinical isolates of M. pneumoniae?

Investigating the correlation between MPN_283 expression and virulence in clinical isolates requires a comprehensive approach combining molecular techniques and clinical data analysis:

For clinical relevance, researchers should analyze samples from varying disease severities (mild, moderate, and severe MPP) and include appropriate controls. This would help determine whether MPN_283 expression correlates with disease progression or if it remains constant regardless of clinical presentation.

What is the functional relationship between MPN_283 and other UPF0134 family proteins in M. pneumoniae?

Understanding the functional relationships among UPF0134 family proteins in M. pneumoniae requires comparative analysis across multiple dimensions:

• Genomic Context Analysis:

  • Examine the genomic neighborhood of MPN_283 and other UPF0134 family genes

  • Identify potential operonic structures suggesting coordinated expression

  • Compare synteny across related Mycoplasma species to identify evolutionary patterns

• Expression Coordination:

  • Perform correlation analysis of expression data across various conditions

  • Cluster UPF0134 proteins based on expression patterns

  • Identify potential regulatory elements common to co-expressed UPF0134 genes

• Protein-Protein Interactions:

  • Conduct systematic interactome studies to identify interactions between UPF0134 proteins

  • Map interaction networks to determine functional clusters

  • Validate key interactions using orthogonal methods (co-IP, FRET, etc.)

• Functional Redundancy Assessment:

  • Generate single and combinatorial knockouts of UPF0134 family proteins

  • Assess phenotypic effects on growth, morphology, and virulence

  • Perform complementation studies to confirm specific functions

• Structural Comparison:

  • Align 3D structures or models of UPF0134 family proteins

  • Identify conserved and variable regions that may relate to shared or unique functions

  • Map conservation patterns onto structural models

M. pneumoniae contains multiple UPF0134 family proteins (including MPN_094, MPN_100, MPN_137, MPN_138, among others) . These proteins may function in redundant pathways, providing robustness to essential cellular processes, or they may have diversified to perform specialized functions. Understanding these relationships is crucial for interpreting the specific role of MPN_283 within the broader functional landscape of M. pneumoniae biology.

What are the optimal conditions for evaluating MPN_283 interactions with host immune system components?

To rigorously evaluate interactions between MPN_283 and host immune components, researchers should consider a multi-tiered experimental approach that progresses from in vitro biochemical assays to more complex cellular and in vivo systems:

• Protein-Protein Interaction Assays:

  • Surface Plasmon Resonance (SPR) or Bio-Layer Interferometry (BLI): For measuring direct binding kinetics to purified immune components

  • ELISA-based binding assays: For screening interactions with multiple immune factors

  • Protein microarrays: For high-throughput identification of potential immune ligands

• Cellular Immunology Approaches:

  • Macrophage/dendritic cell stimulation assays: Measure cytokine production, surface marker expression

  • Flow cytometry: Assess binding to immune cell populations and activation states

  • Confocal microscopy: Visualize localization and co-localization with immune receptors

• Functional Immunology Assays:

  • NFκB reporter assays: Detect activation of inflammatory pathways

  • Inflammasome activation assays: Measure IL-1β production, pyroptosis, ASC speck formation

  • T cell activation/polarization assays: Assess effects on adaptive immunity

• Ex Vivo Systems:

  • Human peripheral blood mononuclear cell (PBMC) responses to MPN_283

  • Precision-cut lung slices to assess responses in respiratory tissue context

  • Bronchoalveolar lavage fluid (BALF) analysis from infected models

• In Vivo Models:

  • Transgenic mice expressing human immune receptors

  • Comparison of wild-type and immune-deficient mouse strains

  • Assessment of immune cell recruitment and activation in vivo

Recent research has demonstrated that M. pneumoniae pathogenesis involves complex immune interactions, with disease progression more strongly correlated with immune responses than bacterial load . Therefore, researchers should pay particular attention to:

• Comparing responses in cells from different donors to account for genetic variation

• Including appropriate positive controls (known PAMPs, other M. pneumoniae components)

• Using both purified recombinant MPN_283 and appropriate expression systems for delivery

• Controlling for potential endotoxin contamination in recombinant preparations

• Distinguishing direct effects from secondary effects mediated by other cellular responses

How can researchers effectively design knockout/knockdown studies for MPN_283 given M. pneumoniae's minimal genome?

Designing genetic manipulation studies for MPN_283 in M. pneumoniae requires careful consideration due to the organism's minimal genome and the potential essentiality of many genes:

• Essentiality Assessment:

  • Transposon mutagenesis screens: Determine if MPN_283 can tolerate insertions

  • Growth curve analysis: Compare growth rates between wild-type and mutant strains

  • Competitive growth assays: Co-culture wild-type and mutant strains to assess fitness

• Knockout Strategy Options:

  • CRISPR-Cas9: Targeted genome editing with repair templates

  • Homologous recombination: Replace MPN_283 with antibiotic resistance marker

  • Suicide vectors: Delivery of knockout constructs that cannot replicate in M. pneumoniae

• Conditional Systems for Essential Genes:

  • Tetracycline-repressible promoters: Control expression levels

  • Destabilization domains: Enable protein degradation upon small molecule addition

  • CRISPRi: Partial repression without complete gene deletion

• Complementation Approaches:

  • Ectopic expression from alternative genomic loci

  • Plasmid-based expression where feasible

  • Trans-complementation with wild-type protein

• Phenotypic Analysis:

  • Growth characteristics in various media and conditions

  • Morphological changes via electron microscopy

  • Virulence assessment in cell culture and animal models

  • Transcriptomic/proteomic analysis of compensatory changes

For the specific case of MPN_283, additional considerations include:

• Using gradual depletion approaches if the gene proves essential

• Examining effects on other UPF0134 family proteins to detect compensatory mechanisms

• Assessing the impact on host-pathogen interactions, particularly immune responses

• Monitoring effects on known virulence mechanisms such as CARDS toxin function

Given M. pneumoniae's minimal genome (~816 kilobases, ~700 genes), researchers should carefully consider the potential for polar effects on adjacent genes and implement appropriate controls to distinguish direct from indirect effects of MPN_283 manipulation.

What analytical techniques are most appropriate for characterizing post-translational modifications of MPN_283?

Comprehensive characterization of post-translational modifications (PTMs) on MPN_283 requires an integrated analytical workflow combining multiple complementary techniques:

For MPN_283 specifically, researchers should consider:

• Expression System Influence: Different expression systems (E. coli, yeast, baculovirus, mammalian cells) will produce varying PTM profiles . Compare PTMs across systems to identify authentic modifications versus expression artifacts.

• Native Context Analysis: When possible, analyze MPN_283 purified directly from M. pneumoniae to establish the native PTM profile as a reference standard.

• Dynamic PTM Assessment: Examine how PTMs change under different growth conditions, during infection stages, or in response to host factors.

• Functional Validation: Generate site-directed mutants at identified PTM sites to assess their functional significance in biochemical and cellular assays.

• Comparative PTM Analysis: Compare PTM patterns between MPN_283 and other UPF0134 family proteins to identify conserved modification patterns that might indicate functional importance.

Given that M. pneumoniae has a reduced genome and consequently fewer enzymes for PTM processing compared to more complex organisms, particular attention should be paid to modifications that could be performed by host factors during infection, as these may play roles in host-pathogen interactions.

What are the critical considerations for designing antibodies or other detection reagents specific to MPN_283?

Developing specific and sensitive detection reagents for MPN_283 requires careful design considerations across multiple dimensions:

• Epitope Selection Strategy:

  • Sequence Analysis: Identify unique regions with minimal homology to other UPF0134 proteins

  • Structural Mapping: Target surface-exposed regions most accessible for binding

  • Antigenicity Prediction: Use algorithms to identify potentially immunogenic sequences

  • Conservation Analysis: Assess epitope conservation across M. pneumoniae strains

• Antibody Development Approaches:

  • Polyclonal Antibodies: Generate against full-length protein or specific peptides

  • Monoclonal Antibodies: Develop from hybridomas for consistent specificity

  • Recombinant Antibodies: Phage display or yeast display for challenging targets

  • Nanobodies: Single-domain antibodies for accessing restricted epitopes

• Validation Requirements:

  • Cross-reactivity Testing: Against other UPF0134 family proteins

  • Sensitivity Determination: Limit of detection in various assay formats

  • Specificity Confirmation: Using knockout/knockdown controls

  • Application-specific Validation: For Western blot, IHC, flow cytometry, etc.

• Alternative Detection Reagents:

  • Aptamers: Nucleic acid-based binding molecules

  • Affimers/Monobodies: Non-immunoglobulin scaffolds

  • CRISPR-based Detection: For nucleic acid detection of MPN_283 gene

  • Mass Spectrometry: Targeted proteomics using signature peptides

• Assay Development Considerations:

  • Sandwich ELISA: Pairs of antibodies recognizing different epitopes

  • Multiplex Detection: Combined detection of MPN_283 with other M. pneumoniae markers

  • Point-of-care Formats: Lateral flow or microfluidic implementations

  • Automation Compatibility: Compatibility with high-throughput screening platforms

How might comparative analysis of MPN_283 across different Mycoplasma species inform evolutionary adaptations to host environments?

Comparative evolutionary analysis of MPN_283 homologs across Mycoplasma species can provide valuable insights into host adaptation mechanisms:

• Phylogenetic Analysis Framework:

  • Construct phylogenetic trees based on MPN_283 sequence across Mycoplasma species

  • Compare with whole-genome phylogenies to identify discordant evolutionary patterns

  • Calculate selection pressures (dN/dS ratios) to identify positively selected regions

  • Map selection patterns onto structural models to identify functionally important domains

• Host-Range Correlation:

  • Compare MPN_283 sequences from Mycoplasma species infecting different hosts

  • Identify sequence signatures associated with specific host adaptations

  • Analyze convergent evolution patterns in species with similar host preferences

  • Examine correlation between MPN_283 variation and host immune system differences

• Functional Domain Conservation:

  • Identify highly conserved regions suggesting core functional importance

  • Compare variable regions that may indicate host-specific adaptations

  • Analyze protein structure conservation versus sequence conservation

  • Identify potential interaction interfaces based on conservation patterns

• Experimental Validation Approaches:

  • Domain swapping between homologs from different species

  • Heterologous expression of MPN_283 variants in model systems

  • Binding assays with host factors from different species

  • Complementation studies in knockout strains

This comparative approach could reveal whether MPN_283 has evolved as a core housekeeping protein with conserved function across Mycoplasma species or has diversified to facilitate adaptation to different host environments. Given the evidence that M. pneumoniae pathogenesis involves specific immune interactions , variation in MPN_283 might correlate with differences in how different Mycoplasma species interact with host immune systems.

Such evolutionary insights would not only enhance our fundamental understanding of Mycoplasma biology but could also inform the development of species-specific diagnostic markers and potentially reveal conserved targets for broad-spectrum therapeutic interventions against multiple Mycoplasma pathogens.

What potential role might MPN_283 play in the development of synthetic biology applications based on M. pneumoniae?

The potential utility of MPN_283 in synthetic biology applications based on M. pneumoniae spans several innovative areas:

• Minimal Genome Engineering:

  • Determine essentiality of MPN_283 for inclusion in synthetic minimal genomes

  • Evaluate functional redundancy with other UPF0134 proteins for genome streamlining

  • Test performance in chassis organisms designed for synthetic biology applications

  • Assess growth and protein production impacts when engineered for optimized expression

• Protein Engineering Applications:

  • Develop MPN_283 as a scaffold for displaying heterologous epitopes or functional domains

  • Engineer chimeric proteins combining MPN_283 with other functional modules

  • Optimize for stability in various expression systems relevant to biotechnology

  • Create biosensor applications based on conformational changes in engineered variants

• Therapeutic Delivery Systems:

  • Evaluate MPN_283 as a component of mycoplasma-based therapeutic delivery systems

  • Develop attenuated M. pneumoniae strains with modified MPN_283 for vaccine applications

  • Engineer cell-targeting capabilities by fusing with cell-specific binding domains

  • Create controllable expression systems for therapeutic protein delivery

• Diagnostic Platform Development:

  • Design MPN_283-based detection systems for M. pneumoniae identification

  • Develop multiplexed diagnostic arrays incorporating multiple Mycoplasma proteins

  • Create point-of-care testing platforms targeting MPN_283 gene or protein

  • Engineer reporter systems based on MPN_283 promoter activity

Given the minimal genome of M. pneumoniae and its natural tropism for the respiratory epithelium, the organism has potential as a specialized chassis for synthetic biology applications targeting respiratory conditions. Understanding the function of MPN_283 and its interactions could facilitate the development of synthetic biology tools that leverage the unique properties of M. pneumoniae while mitigating pathogenicity concerns.

The recent advances in understanding M. pneumoniae immune interactions and virulence mechanisms provide a foundation for engineering safer synthetic biology platforms based on this organism, potentially incorporating modified versions of MPN_283 designed for specific biotechnological applications.

How might high-throughput functional screening approaches identify unexpected functions of MPN_283?

High-throughput functional screening offers powerful approaches for uncovering novel functions of MPN_283:

• Phenotypic Screening Platforms:

  • CRISPR Activation/Interference: Modulate MPN_283 expression in different cell backgrounds

  • Arrayed Overexpression: Express MPN_283 in diverse cell types to identify phenotypic changes

  • Chemical-Genetic Interaction: Screen for compounds with differential effects on MPN_283-expressing cells

  • Synthetic Lethal Screening: Identify genes whose loss is specifically lethal with MPN_283 alteration

• Molecular Interaction Screening:

  • Yeast Two-Hybrid: Identify protein interaction partners from host and pathogen proteomes

  • Protein Complementation Assays: Screen for functional interactions in cellular contexts

  • Protein Microarrays: Test binding to thousands of potential interaction partners

  • Ribosome Display: Evolve high-affinity binding proteins to identify functional domains

• Omics-Based Functional Discovery:

  • RNA-Seq: Transcriptional consequences of MPN_283 expression or deletion

  • Proteomics: Changes in protein abundance, modifications, and complexes

  • Metabolomics: Metabolic pathway alterations associated with MPN_283 function

  • Lipidomics: Effects on membrane composition and signaling lipids

• Computational Screening Integration:

  • Network Analysis: Position MPN_283 in functional interaction networks

  • Machine Learning: Predict functions based on patterns from high-throughput data

  • Systems Biology Modeling: Integrate multi-omics data to predict functional roles

  • Evolutionary Analysis: Identify co-evolving genes suggesting functional relationships

• Validation Approaches:

  • Orthogonal Assays: Confirm hits using independent methodologies

  • Domain Mapping: Define functional regions through truncation and mutation analysis

  • Biochemical Characterization: Purify protein complexes for detailed functional studies

  • In Vivo Validation: Test predicted functions in animal models of infection

This multi-dimensional screening approach could reveal unexpected functions beyond current annotations, potentially identifying roles in processes such as:

• Host immune modulation, given the importance of immune responses in MPP pathogenesis

• Post-translational modification of host or bacterial proteins

• Regulation of virulence factor expression or activity, similar to mechanisms observed with CARDS toxin

• Metabolic adaptations specific to the host environment

• Stress response mechanisms during infection